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Introduction: Performance status (PS) 2 patients with non-small
cell lung cancer (NSCLC) experience more toxicity, lower response
rates, and shorter survival times than healthier patients treated with
standard chemotherapy. Paclitaxel poliglumex (PPX), a macromol-
ecule drug conjugate of paclitaxel and polyglutamic acid, reduces
systemic exposure to peak concentrations of free paclitaxel and may
lead to increased concentrations in tumors due to enhanced vascular
permeability.
Methods: Chemotherapy-naive PS 2 patients with advanced
NSCLC were randomized to receive carboplatin (area under the
curve  6) and either PPX (210 mg/m2/10 min without routine
steroid premedication) or paclitaxel (225 mg/m2/3 h with standard
premedication) every 3 weeks. The primary end point was overall
survival.
Results: A total of 400 patients were enrolled. Alopecia, arthralgias/
myalgias, and cardiac events were significantly less frequent with
PPX/carboplatin, whereas grade 3 neutropenia and grade 3 neu-
ropathy showed a trend of worsening. There was no significant
difference in the incidence of hypersensitivity reactions despite the
absence of routine premedication in the PPX arm. Overall survival
was similar between treatment arms (hazard ratio, 0.97; log rank p
0.769). Median and 1-year survival rates were 7.9 months and 31%,
for PPX versus 8 months and 31% for paclitaxel. Disease control
rates were 64% and 69% for PPX and paclitaxel, respectively. Time
to progression was similar: 3.9 months for PPX/carboplatin versus
4.6 months for paclitaxel/carboplatin (p  0.210).
Conclusion: PPX/carboplatin failed to provide superior survival
compared with paclitaxel/carboplatin in the first-line treatment of PS
2 patients with NSCLC, but the results with respect to progression-
free survival and overall survival were comparable and the PPX
regimen was more convenient.
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Patients with non-small cell lung cancer (NSCLC) usuallypresent with inoperable, advanced disease. Untreated,
these patients have a 1-year survival rate of approximately
10%.1 Combination chemotherapy regimens provide a statis-
tically significant survival benefit, with 1-year survival rates
of 30% to 40% in performance status (PS) 0 to 1 individuals
and 2-year survival rates exceeding 10%.2–5 Retrospective
reviews and meta-analyses of phase III trials have shown that
patients with compromised PS (e.g., PS 2) have significantly
impaired survival compared with PS 0 to 1 patients.6–8 This
may be due to highly aggressive disease or comorbid condi-
tions and impaired organ function, which can exacerbate
chemotherapy toxicity. Consequently, PS 2 patients are often
excluded from chemotherapy trials. Toxicity may deter cli-
nicians from using standard platinum-based combination reg-
imens for PS 2 patients, who often receive palliative care or
single-agent, non-platinum therapy instead.
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A recent, prospectively planned subanalysis of Cancer
and Leukemia Group B (CALGB) 9730, however, demon-
strated that PS 2 patients benefited from platinum-based
combination therapy compared with a single agent.9 Of the
nearly 600 patients enrolled in CALGB 9730, 99 were PS 2.
Within this cohort, overall response rate, median survival,
and 1- and 2-year survival rates were 24%, 4.7 months, 18%,
and 9% for the paclitaxel/carboplatin regimen versus 10%,
2.4 months, 10%, and 0% for single-agent paclitaxel.
Paclitaxel poliglumex (PPX) is an anionic, polymeric
macromolecule consisting of paclitaxel conjugated to glu-
tamic acid residues.10 The large number of anionic charges
renders this molecule water soluble. The ester bond between
paclitaxel and the polyglutamate backbone is stable and resistant
to spontaneous hydrolysis; therefore, PPX is not broken down
by plasma esterases. Consequently, the circulating polymer is
relatively less toxic to normal tissue and theoretically better at
delivering paclitaxel to the target cells.11 Aqueous solubility
also permits rapid intravenous administration and obviates
the need for toxic solubilizing agents such as Cremophor.
Finally, this molecule capitalizes on enhanced tumor perme-
ability and retention of macromolecules to maximize tumor
paclitaxel exposure.
Preclinical models demonstrated activity in NSCLC
lines and synergy with platinating agents, including carbo-
platin.12,13 In a phase II trial of 28 patients with treatment-naive
advanced NSCLC, PPX at a dose of 175 mg/m2 every 3 weeks
yielded a median survival of 8.1 months in a PS 0 to 1
population and 5.4 months in a PS 2 cohort. In phase I trials,
PPX has been combined at doses as high as 225 mg/m2 every
3 weeks with carboplatin (area under the curve [AUC]  6)
without untoward short-term toxicity.14 Based on cumulative
neurotoxicity, the recommended phase II dose in this setting
was 210 mg/m2.
The observations from the phase II single-agent trial,
the ability to combine PPX at full dose with standard doses of
carboplatin, its convenient administration, and the potential
of decreased toxicity compared with standard paclitaxel laid
the groundwork for a phase III trial, PGT303. This trial, also
known as Selected Targeted Efficacy in Lung Cancer to
Lower Adverse Reactions 3 (STELLAR 3), compared stan-
dard paclitaxel/carboplatin with PPX/carboplatin in PS 2
patients.
MATERIALS AND METHODS
Study Design
This open-label, phase III study compared paclitaxel
225 mg/m2 with PPX at 210 mg/m2 each in combination with
carboplatin (AUC  6) given every 3 weeks for up to 6
cycles. Patients were excluded from the study for disease
progression (PD), intolerable toxicity, withdrawal of consent,
or investigator discretion.
Randomization was stratified based on disease stage
(IV versus other), gender, history of brain metastases, and
geographic location (US versus Western Europe/Canada ver-
sus Eastern Europe).
Antiemetic prophylaxis was permitted for carboplatin
including dexamethasone to prevent delayed nausea and
vomiting. The paclitaxel arm required routine hypersensitiv-
ity prophylaxis; however, the use of routine antihistamines or
hypersensitivity prophylaxis was prohibited on the PPX arm.
Hematopoietic growth factor support was permitted accord-
ing to American Society of Clinical Oncology guidelines.15
End Points
The primary study end point was survival. Secondary
objectives included response rate, time to progression (TTP),
safety, and quality of life. Radiographic response was as-
sessed every 2 cycles. For patients who completed therapy
without evidence of PD, indicator lesions were re-evaluated
every 8 weeks until documentation of PD or start of second-
line therapy.
Safety data were collected on all patients. Disease-
related symptoms were measured by the Functional Assess-
ment of Cancer Therapy Lung Cancer Subscale (FACT-LCS)
at baseline and within 3 days of each treatment.
Eligibility Criteria
All enrollees had histologically or cytologically con-
firmed NSCLC, an Eastern Cooperative Oncology Group
(ECOG) PS 2 and stage IV, stage IIIb (but not candidates for
combined modality therapy with curative intent), or locally
advanced or recurrent disease previously treated with radia-
tion and/or surgery. Eligibility stipulated age 18 years;
adequate organ function, including baseline absolute neutro-
phil count 1500/L; platelet count 100,000/L; creati-
nine1.5 times the upper limit of normal (ULN); bilirubin
ULN; transaminases 2.5 times ULN (5 times ULN in
patients with hepatic metastases); and alkaline phosphatase
2.5 times ULN, unless bone metastases were present. Pa-
tients with stable, treated brain metastases were eligible.
Adequate contraception was required for female patients of
reproductive potential.
Exclusion criteria included any small cell or carcinoid
histology; prior systemic therapy for NSCLC; active, un-
treated brain metastases; other active primary invasive ma-
lignancies requiring treatment; grade 2 neuropathy; clini-
cally significant infection; exposure to other investigational
agents within 4 weeks of study entry; and unstable concom-
itant medical conditions. The protocol was approved by the
institutional review board at each participating institution. All
patients gave informed consent.
Representative case report forms were carefully re-
viewed to make certain that patient characteristics supported
PS 2 designations.
Efficacy Parameters and Statistical
Considerations
Overall survival was defined as the interval between
randomization and death from any cause. Patients remaining
alive, including those lost to follow-up, were censored at the
date of last contact. Nonstratified log-rank testing was used
for the formal primary comparison of survival. This study
targeted accrual of 370 evaluable patients with 80% power
and 0.05 type I error to show a 1.5-month improvement in
median survival from a projected baseline of 4 to 5.5 months.
In addition, secondary analyses were conducted using Cox
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regression models of prognostic factors associated with sur-
vival in patients with NSCLC.
Response was assessed by response evaluation criteria
in solid tumors.16 Disease control was determined by the
percentage of patients alive without PD for at least 12 weeks.
A two-sided Fisher exact test with an  level of 0.05 for
statistical significance was used. TTP was defined as the
interval between randomization and PD and was analyzed
using an unstratified log-rank test. Toxicities were compared
between the treatment arms using the Fisher’s exact test.
Quality of Life
Disease-related symptoms were measured by the
FACT-LCS, a validated, five-point Likert-type scale ranging
from 0 (not at all) to 4 (very much). The total LCS score
ranged from 0 to 28, with higher scores indicative of fewer
symptoms. The percentage of patients with at least two-point
improvements in their LCS scores at the beginning of cycle 2
was compared by treatment arm.
RESULTS
Disposition of Patients
Four hundred patients were enrolled between Decem-
ber 2002 and December 2003; 199 patients were assigned to
the PPX arm and 201 to the paclitaxel arm. Three patients, all
in the paclitaxel treatment arm, did not receive study treat-
ment: one developed PD before starting therapy, a second had
an elevated baseline bilirubin and did not meet eligibility
criteria, and a third was withdrawn from the study due to
rapid PD and intercurrent pneumonitis.
The arms were well balanced with regard to baseline
characteristics (Table 1). Seventy-seven percent of patients
were male, 94% white, and 63% from Eastern Europe. Me-
dian age was 61 years on the PPX arm and 63 years on the
paclitaxel arm. Seventy-three percent of patients had stage IV
disease, and 7% had brain metastases at baseline. Russia
contributed the largest proportion of patients (35%), followed
by the United States (23%). The differences between Eastern
European enrollees and their Western European, US, and
Canadian counterparts are delineated in Table 2.
Treatment Completion Rates
The median number of cycles was four in each arm. In
the PPX arm, 27% of patients completed six cycles of therapy
compared with 36% in the paclitaxel arm (p  0.0411;
Fisher’s exact test). The most frequent reasons for stopping
treatment were PD (36% versus 34%, respectively) and
adverse effects (27% versus 20%, respectively). Nine percent
of patients withdrew consent in the PPX arm compared with
6% in the paclitaxel arm.
Efficacy
Median overall survival was 7.8 months in the PPX arm
and 7.9 months in the paclitaxel arm (Fig. 1A). One-year sur-
vival was identical at 31%. The 18- and 24-month survival rates
were numerically higher in the PPX arm (20 and 13%, respec-
tively) compared with the paclitaxel arm (11 and 11%, respec-
tively), but these differences were not statistically significant.
TABLE 1. Demographic and Baseline Characteristics
PPX/Carboplatin
(n  199)
Paclitaxel/Carboplatin
(n  201)
Gender
Male 151 (76%) 156 (78%)
Female 48 (24%) 45 (22%)
Race
White 189 (95%) 188 (94%)
Black 8 (4%) 9 (5%)
Asian 2 (1%) 1 (1%)
Hispanic 0 (0%) 2 (1%)
Other 0 (0%) 1 (1%)
Age at randomization, (yr)
Mean (SD) 61.1 (10.6) 61.5 (10.1)
Median (range) 61.0 (35–86) 63.0 (36–89)
Geographic site
United States 46 (23%) 45 (22%)
Western Europe and
Canada
30 (15%) 27 (13%)
Eastern Europe 123 (62%) 129 (64%)
Stage at randomization
IIIa 2 (1%) 0 (0%)
IIIb 51 (26%) 55 (27%)
IV 146 (73%) 146 (73%)
History of brain metastases
Yes 14 (7%) 15 (7%)
No 185 (93%) 186 (93%)
Smoking history
Yes 170 (85%) 171 (85%)
No 29 (15%) 30 (15%)
PPX, paclitaxel poliglumex; SD, standarddeviation.
TABLE 2. Demographic and Baseline Characteristics at
Entry Based on Region
Region
US/Western
Europe/Canada
(n  148)
Eastern
Europe
(n  252)
5% weight loss within 6 mo of
randomization
58 (39%) 104 (41%)
Histologic diagnosis
Squamous cell carcinoma 43 (29%) 134 (53%)
Adenocarcinoma 78 (53%) 72 (29%)
Other 27 (18%) 46 (18%)
Stage at enrollment
Stage IV/recurrent 122 (82%) 170 (67%)
Stage IIIb 26 (18%) 80 (32%)
History of brain metastases 21 (14%) 8 (3%)
Prior radiation 47 (32%) 40 (16%)
Median FACT-LCS score 18.7 17.0
Current use of tobacco 46 (31%) 113 (45%)
Baseline opioid use 19 (13%) 12 (5%)
Baseline hemoglobin 11 g/dL 110 (74%) 220 (87%)
FACT-LCS, functional assessment of cancer therapy lung cancer subscale.
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Prespecified analyses by stratification factors (Table 3)
demonstrated that median survival in the paclitaxel arm was
significantly better in Eastern Europe and Russia than in the
United States and Western Europe (9.4 versus 6.3 months;
p  0.003; Fig. 1B). There was less difference in median
survival on the PPX arm (8.2 versus 6.7 months; p  0.029;
Fig. 1C). Women on the paclitaxel arm had a median survival
similar to those in the experimental arm (8.3 versus 7.9
months). However, at 12, 18, and 24 months, survival rates
were better on PPX compared with paclitaxel (37 versus
25%, 26 versus 5%, and 13 versus 5%, respectively). Survival
for men was similar in both arms with virtually identical
median survival (7.9 versus 7.9 months) and 1- (29 versus
33%) and 2-year (13 versus 13%) survival rates.
Cox multivariate stepwise modeling, with all other factors
constant, demonstrated that weight loss before study entry,
tobacco use, elevated lactate dehydrogenase levels, and elevated
calcium levels significantly increased the probability of death.
Response and TTP
The overall response rate was 20% for the PPX arm
with 1% complete responses and 37% for the paclitaxel arm
with 2% complete responses; these results significantly fa-
vored the paclitaxel arm (Table 4). Blended response rates
differed by geographic region: 35% for Eastern Europe, 23%
for Western Europe and Canada, and 14% for the United
States. Disease control rate was 64% in the PPX arm, com-
pared with 69% in the paclitaxel arm.
Median TTP was 3.9 months in the PPX arm and 4.6
months on the paclitaxel arm (p  0.210). The proportion of
patients receiving subsequent therapy and the type of therapy
administered were not different in the 2 arms. Eighteen
percent of those enrolled in the PPX arm went on to radiation
therapy, compared with 13% in the paclitaxel arm. Nearly
50% in each arm received additional chemotherapy; no spe-
cific agents predominated. Roughly 7% of patients received
epidermal growth factor receptor tyrosine-kinase inhibitors as
second-line or subsequent therapy.
Quality of Life
FACT-LCS evaluations were completed by 180 pa-
tients on the PPX/carboplatin arm and 172 patients on the
paclitaxel/carboplatin arm. No significant difference in the
FACT-LCS scores was seen.
Toxicity
Drug Delivery
Patients received nearly 90% of planned doses during the
second and subsequent cycles. The mean delivered dose inten-
sity per cycle was comparable in both arms. In Eastern Europe,
75% of patients received 4 to 6 cycles, compared with 44 and
49% in the United States and Western Europe/Canada, respec-
tively. The mean normalized carboplatin dose per cycle per
patient was the same for both arms (AUC  5.6).
Relative Toxicities
Patients enrolled in the paclitaxel arm were signifi-
cantly more likely to experience cardiac toxicity, alopecia,
and musculoskeletal toxicity (Table 5). However, those in the
PPX arm experienced significantly more nausea and vomit-
ing. More grade 3/4 neuropathy was seen on the PPX arm (17
versus 10%), but this difference was not statistically signifi-
cant. Time to first manifestation of neuropathy was generally
later in the PPX arm—a median of 89 days compared with 54
days for the paclitaxel arm (log-rank p 0.001). By day 100,
the incidence was equal. Fatigue was higher in the PPX arm
than the paclitaxel arm: 15 versus 8% (p  0.05); however,
FIGURE 1. Overall survival using Kaplan-Meier estimation.
(A) Paclitaxel poliglumex/carboplatin versus paclitaxel/carbo-
platin. (B) Paclitaxel/carboplatin—United States/Western
Europe/Canada versus Eastern Europe. (C) PPX/carboplatin—
United States/Western Europe/Canada versus Eastern Europe.
Langer et al. Journal of Thoracic Oncology • Volume 3, Number 6, June 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer626
grade 3/4 fatigue was similar between arms: 2 versus 3%
(p  0.66).
The incidence of grade 3/4 thrombocytopenia was sig-
nificantly higher in the PPX arm (p  0.001) but was not
associated with more thrombocytopenic bleeding or higher
transfusion requirements. Five percent of patients on the PPX
arm required platelet transfusions, compared with 3% on the
paclitaxel arm (p  0.42). The incidence of febrile neutro-
penia was 6% in the PPX arm versus 3% in the paclitaxel arm
(p  0.32). The reported incidence of neutropenia in Eastern
Europe was 24%, compared with 47% in the United States
and 42% in Western Europe/Canada. The use of supportive
care, including transfusions, erythropoietin, and granulocyte
colony-stimulating factor, was similar between treatment
arms but different based on geographic regions. The use of
red blood cell growth factor support in the United States/
Western Europe/Canada was 38% compared with less than
1% in Eastern Europe (p 0.001); the use of white blood cell
growth factor support in the United States/Western Europe/
Canada was 31% compared with 7% in Eastern Europe (p 
0.001). Seven percent of those in Eastern Europe required red
blood cell transfusions compared with 16% in the United
States/Western Europe/Canada (p  0.006).
Twelve percent of patients in each arm died within 30
days of treatment, but only 1% of all deaths were attributable
to study drugs. There were 7.5% disease-related deaths, and
3.5% were due to comorbidities.
Total infusion time for the PPX combination was 48
minutes, compared with 224 minutes for the paclitaxel com-
bination. The incidence of hypersensitivity reactions was 2%
for the paclitaxel/carboplatin arm with standard premedica-
tions of steroids and H1 and H2 blockers, compared with 1%
for the PPX/carboplatin arm without routine hypersensitivity
reaction prophylaxis. However, 28% of PPX patients, mostly
in the United States and Canada, received steroid prophylaxis
and/or antihistamines beginning in cycle 1 as antiemetic
prophylaxis for carboplatin.
DISCUSSION
STELLAR 3 is the first dedicated phase III trial ever
conducted and reported in treatment-naive PS 2 patients with
TABLE 3. Subgroup Analysis of Overall Survival
Subgroup
PPX/Carboplatin Paclitaxel/Carboplatin
Hazard Ratioa
Log-Rank
Test; pn
Median Survival,
d (95% CI) n
Median Survival,
d (95% CI)
Overall 199 237 (205–271) 201 239 (206–287) 0.97 (0.78–1.21) 0.769
Gender
Male 151 237 (199–275) 156 239 (204–288) 1.04 (0.80–1.34) 0.780
Female 48 236 (174–380) 45 248 (167–323) 0.76 (0.48–1.20) 0.239
Geographic location
United States 46 217 (164–291) 45 173 (100–248) 0.79 (0.50–1.23) 0.298
Western Europe/Canada 30 188 (118–275) 27 206 (103–322) 1.08 (0.63–1.86) 0.773
Eastern Europe 123 249 (219–326) 129 287 (233–347) 1.00 (0.75–1.33) 0.992
Disease stage at randomization
IV 146 237 (189–283) 146 236 (205–277) 0.92 (0.71–1.19) 0.528
Other 53 246 (182–311) 55 274 (181–404) 1.09 (0.70–1.70) 0.715
History of brain metastases
Yes 14 207 (145–320) 15 229 (87–328) 1.13 (0.51–2.50) 0.770
No 185 237 (206–275) 186 239 (206–292) 0.97 (0.77–1.22) 0.778
a Hazard ratio (CT-2103 to paclitaxel) was estimated by Cox regression with treatment arm as a single covariate.
PPX, paclitaxel poliglumex; CI, confidence intervals.
TABLE 4. Efficacy Results in the Intent-to-Treat Population
PPX/Carboplatin Paclitaxel/Carboplatin
No. patients 199 201
Survival
Median (d) 237 239
95% CI 205–271 206–287
Hazard ratio (95% CI);
log-rank p value
0.97 (0.78–1.21); 0.769
1-yr survival rate (%) 31 31
95% CI 24–37 25–38
2-yr survival rate (%) 13 11
95% CI 5–22 4–18
Time to progression
Median (d) 118 139
95% CI 100–129 118–156
Hazard ratio (95% CI);
log-rank p value
1.14 (0.93–1.40); 0.210
Disease control, %
(95% CI)
64 (57–0) 69 (62–75)
Response rate (patients
with measurable
disease only)
No. patients 191 192
PR  CR, % (95% CI) 20 (15–27) 37 (30–44)
Confirmed PR  CR, %
(95% CI)
13 (9–19) 28 (22–35)
PPX, paclitaxel poliglumex; CI, confidence intervals; PR, partial response; CR,
complete response.
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NSCLC. Based on the preplanned statistical analysis, PPX
failed to yield superior survival compared with paclitaxel in
this setting, the primary end point, but disease control rates,
TTP, and overall survival rates were comparable, as was dose
delivery. Hence, potential utility for PPX in the PS 2 popu-
lation still exists.
An unplanned subanalysis of women enrolled in this study
by baseline estradiol levels, reported at the American Society of
Clinical Oncology annual meeting in 2006, demonstrated a
significant survival advantage for PPX in women with premeno-
pausal estradiol levels (30 pg/mL).17 This observation will be
prospectively evaluated in a phase III study.
The overall survival for PS 2 patients enrolled in this
trial was substantially longer than expected based on previ-
ously reported data. In the Lilenbaum et al. study (CALGB
9730),9 the median survival for PS 2 patients receiving
paclitaxel and carboplatin was 4.7 months, compared with
nearly 8 months for both arms in this trial. A previous phase
II study of PPX alone at a lower dose of 175 mg/m2 showed
survival of 5.4 months in the PS 2 cohort. Whereas survival
in North America and Western Europe mirrored recent expe-
rience with carboplatin and paclitaxel in PS 2 patients (Table
6), Eastern Europe differed substantially with far better sur-
vival observed in both arms. This may be due to a younger
population with fewer comorbidities, less prior radiation, less
advanced disease, less baseline anemia, and possibly lower
incidence of readily recognizable central nervous system
metastases. It may also be due to “contamination” by PS 0 to
1 patients, although auditing of case report forms does not
support this theory, and there are no known geographic
differences in the nature of PS evaluation. Still, PS designa-
tion remains highly subjective and open to debate.
PPX/carboplatin produced fewer myalgias and arthral-
gias, less alopecia, and delayed time to neuropathy, but more
nausea, vomiting, and fatigue and overall worse neuropathy
than paclitaxel/carboplatin. The increased incidence of nau-
sea and vomiting in the PPX arm may have been due to lack
of routine premedication for hypersensitivity reaction. Febrile
neutropenia rates were comparable in each arm. Although the
incidence of grade 3 thrombocytopenia was significantly
higher for the PPX arm, it was readily manageable and did
not result in more platelet transfusions. PPX administration
was also more convenient than paclitaxel with a significantly
shorter administration time (48 versus 224 minutes) and no
significant increase in hypersensitivity reactions despite the
absence of routine premedication.
TABLE 5. No. (%) Patients with Treatment-Related Adverse Effects by Maximum NCI Common Toxicity Grade
Adverse Effects
PPX/Carboplatin (n  199) Paclitaxel/Carboplatin (n  198)
All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4
Nonhematologic
Infection and infestation 5 (3%) 1 (1%) 1 (1%) 4 (2%) 1 (1%) 0
Neuropathy 99 (50%) 30 (15%) 3 (2%) 117 (59%) 18 (9%) 1 (1%)
Cardiac 0 0 0 6 (3%) 1 (1%) 0
Alopecia 27 (14%) 0 0 83 (42%) 0 0
Arthralgia 13 (7%) 2 (1%) 0 33 (17%) 2 (1%) 0
Myalgia 17 (9%) 2 (1%) 0 29 (15%) 5 (3%) 0
Fatigue 29 (15%) 4 (2%) 0 16 (8%) 5 (3%) 0
Nausea 97 (49%) 9 (5%) 0 70 (35%) 10 (5%) 0
Vomiting NOS 59 (30%) 8 (4%) 0 39 (20%) 3 (2%) 1 (1%)
Hematologic
Neutropenia 72 (36%) 18 (9%) 35 (18%) 53 (27%) 14 (7%) 17 (9%)
Febrile neutropenia 11 (6%) 4 (2%) 5 (3%) 5 (3%) 2 (1%) 2 (1%)
Thrombocytopenia 72 (36%) 38 (19%) 5 (3%) 25 (13%) 14 (7%) 0
NCI, National Cancer Institute; PPX, paclitaxel poliglumex; NOS, not otherwise specified.
TABLE 6. Comparative Analysis of Taxane-Based Regimens in Treatment-naïve PS 2
NSCLC in North America
Study Regimen No. Patients Median Survival (mo) 1-yr Survival (%)
CALGB 97308 Paclitaxel 50 2.4 10
CALGB 97308 Paclitaxel/carboplatin 49 4.7 19
ECOG 15944 Paclitaxel/carboplatin 15 4.6 13
ECOG 15996 Paclitaxel/carboplatin 38 6.1 19
PGT303 Paclitaxel/carboplatin 201 8.0 31
PGT303 PPX/carboplatin 199 7.9 31
PS, performance status; NSCLC, non-small cell lung cancer; CALGB, Cancer and Leukemia Group B; ECOG, Eastern
Cooperative Oncology Group; PPX, paclitaxel poliglumex.
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The toxic death rates in this study were comparable
with those observed in recent trials including ECOG 1594,
ECOG 1599, and CALGB 9730.4,9,18 The reduction in toxic
deaths compared with trials completed in the 1990s and
earlier is likely due to better ancillary and supportive care
management. The optimal approach to patients with NSCLC
remains unknown, particularly in patients with compromised
PS. STELLAR 3 showed that two platinum-based doublets
are relatively well-tolerated with better than expected sur-
vival rates in PS 2 patients. The results of STELLAR 4, in
which PPX at a dose of 175 mg/m2 was compared with
investigators’ choice of single-agent gemcitabine or vinorel-
bine as front-line therapy for PS 2 patients and overall median
survival exceeded 7 months, suggested that the addition of a
platinating agent may not necessarily confer a survival ben-
efit.19 Safety analysis of STELLAR 4 suggested a similar
outcome and less neuropathy and neutropenia for the 175
mg/m2 PPX dose compared with the 210 mg/m2 dose used in
STELLAR 3. No published PS 2-specific phase III trial to
date has compared a platinum combination with a nonplati-
num single agent. In the absence of a proven dose response
for taxanes in NSCLC, and given the similar survival rates in
STELLAR 3 and 4, future studies of PPX in NSCLC will be
conducted at a dose of 175 mg/m2.
In a Cox multivariate analysis of prognostic factors, the
most significant negative prognostic factors included ex-
trathoracic metastasis (p  0.006), antecedent weight loss
5% (p  0.006), and LCS score 18 (p  0.019). Geo-
graphic site (Eastern Europe versus Western Europe/United
States/Canada) had a clear-cut bearing on outcome (p 
0.001). These factors should be considered as stratifications
in future trials.
Several other strategies are under investigation in the
PS 2 population. The Southwest Oncology Group recently
reported the results of a phase II trial investigating the role of
erlotinib in PS 2 patients20; and the CALGB has completed a
PS 2-specific, randomized phase II trial evaluating docetaxel
in combination with either bortezomib or cetuximab.21
Other chemotherapy “only” studies are also in progress.
Gridelli et al.22 are completing a randomized phase II trial of
pemetrexed either alone or followed after two cycles by
gemcitabine in advanced NSCLC patients unsuitable for
platinum-based treatment. To date, the sequential arm has not
shown superiority to the single-agent arm.22 US Oncology, in
a phase III trial, is comparing gemcitabine alone to combi-
nation gemcitabine/carboplatin. Single-agent versus doublet
chemotherapy has been tested in several European trials in
“elderly” NSCLC patients with somewhat conflicting results,
but has never been tested exclusively in PS 2 patients.
CONCLUSIONS
PS 2 patients constitute a sizable percentage of new
NSCLC patients; yet they have been largely excluded from or
underrepresented in clinical trials in the last 10 to 15 years
based on a general perception of overall poor outcome.
Single-agent therapy is considered by many to be the standard
approach despite data showing a benefit of combination
therapy. The results of STELLAR 3 confirmed the tolerability
and efficacy of doublet treatment with carboplatin plus either
PPX or paclitaxel. Future studies in PS 2 patients should focus
on the nature of comorbidities, pretreatment disease character-
istics, treatment-related quality of life, and toxicity management.
Patients with poor PS require special attention to ensure clini-
cally meaningful therapeutic benefits. In this vein, newer che-
motherapeutics such as PPX have a potential role.
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